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A B S T R A C T
The aim was to estimate outpatient consumption of psychotropic drugs in Croatia in correlation with Scandinavian
countries. Data on drug utilization, from Zagreb Municipal Pharmacy, were used to calculate the number of defined
daily doses (DDD) and DDD per 1000 inhabitants per day (DDD/TID) using Anatomical-Therapeutic-Chemical method-
ology(ATC) by WHO. Data of the Nordic Medico-Statistical Committee were used for Scandinavian countries. In Zagreb,
total utilization of psychopharmaceuticals of 144.9 DDD/TID in 2001, 148.9 DDD/TID in 2002 and 141.9 DDD/TID in
2003. The anxiolytic/antidepressant ratio decreased in Zagreb by 35.19% (7.19 in 2001 and 4.66 in 2003), whereas in
Scandinavian countries it showed a constant rate (0.7 in Finland, 0.4 in Denmark and Norway, and 0.3 in Sweden). The
three-year utilization patterns show that Croatia has been ever more closely following Scandinavian countries although
there have been a notable differences between Croatia and Scandinavian countries.
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Introduction
The pharmaceutical system reform is part of the over-
all health care reform that has been under way in the Re-
public of Croatia. These changes should also include es-
tablishment of a national drug policy to cover, among
other elements, uniform prescription guidelines for psy-
chiatric drugs, and measures for their implementation
and evaluation. According to Intercontinental Marketing
Service (IMS) data, the leading groups of drugs utilized
worldwide are cardiovascular drugs, immediately fol-
lowed by central nervous system (CNS) drugs with a con-
tinuous annual rise of 11%1. A similar pattern has been
observed in Croatia, with a predominance of cardiovascu-
lar drugs followed by CNS drugs2–4. There have been no
studies assessing the justifiability of such a high utiliza-
tion of these drugs. These data stimulated us to under-
take the present study.
The objectives of the study were: 1) to determine the
outpatient utilization of psychopharmaceuticals in Za-
greb, the capital of Croatia; 2) to compare the outpatient
utilization of psychiatric drugs and their prescription
quality between Zagreb and Scandinavian countries us-
ing the World Health Organization Anatomical-Thera-
peutic-Chemical classification system (ATC)/Defined
Daily Doses (DDD) methodology (ATC/DDD methodol-
ogy); and 3) to propose appropriate interventions in
Zagreb on the basis of the results obtained. Zagreb ac-
counts for about 18% of the Croatian population and 43%
of the Croatian health resources, thus quite reliably rep-
resenting the trends in Croatia as a whole, where the
prescribing quality is likely to be equal or lower. Using
the ATC/DDD methodology, the data obtained can be
compared with other settings and between different time
periods. Scandinavian countries were chosen for their
long tradition of drug utilization monitoring by use of
ATC/DDD methodology and availability of the respective
data on the Internet5.
Materials and Methods
Data on the outpatient utilization of psycholeptics
and psychoanaleptics (ATC groups N05 and N06) in the
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City of Zagreb were collected during 2001, 2002 and
2003. Data on the size and number of packages, and fi-
nancial data based on wholesale price were obtained
from state-owned pharmacies for each individual drug.
These pharmacies accounted for 15% in 2002, and 16% in
2001 and 2003 of all pharmacies in the City of Zagreb.
Pharmacies make an integral part of health care service
and are subject to a number of statutory obligations. Up
to 1991, only state-owned pharmacies existed in Croatia.
When Croatia gained independence, new private phar-
macies started to function. There are no differences be-
tween the state-owned and private pharmacies with re-
gard to their status. All drugs were classified according to
ATC system. Based on the data obtained, the number of
DDD and DDD per 1000 inhabitants per day (DDD/1000/
day) were calculated for all N05 and N06 drugs using
ATC indexes with DDDs for 2001, 2002 and 20036–8. The
reasons for data collection exclusively from state-owned
pharmacies have been previously explained9. On DDD/
1000/day calculation, data from the latest 2001 census
were used, according to which the population of the City
of Zagreb was 770,058. Total outpatient utilization of
ATC N05 and N06 prescription drugs, utilization distri-
bution of these groups of drugs at secondary, tertiary and
quaternary level, and consumption of individual drugs
were analyzed. Data published by the Nordic Medico-Sta-
tistical Committee were employed on analyzing the re-
spective drug utilization in Scandinavian countries5. In
Norway and Finland, data were collected from wholesal-
ers, and in Denmark and Sweden on the basis of pre-
scriptions. Outpatient drug utilization for Finland was
calculated by subtracting inpatient drug utilization from
total drug utilization10, whereas the data on Norway in-
clude inpatient drug utilization as well. The Drug Utili-
zation 90% (DU90%) method was used as a criterion of
prescribing quality9,11. In order to compare drug costs
with other national reports, additional indicators of ra-
tional drug utilization were also determined, e.g., cost
per DDD within DU90% segment (cost/DDD); cost/DDD
for drugs beyond DU90% segment; and cost/DDD for all
psychopharmaceuticals analyzed.
Results
Total utilization of psycholeptics and psychoanalep-
tics (N05 and N06) is presented in Table 1. Total utiliza-
tion of psychopharmaceuticals was highest in Zagreb and
lowest in Denmark. However, while in Scandinavian
countries the utilization of these drugs was on a continu-
ous increase from 2001 to 2003 (the increase being low-
est in Sweden, then in Finland, Denmark and highest in
Norway with 5.6%, 9.9%, 10.1% and 11.5%, respectively),
in Zagreb the utilization of psychopharmaceuticals in
2003 decreased by 2.1% and 4.2% vs. 2001 and 2002, re-
spectively. Table 1 shows a notable difference between
Zagreb and Scandinavian countries in the utilization dis-
tribution of psycholeptics and psychoanaleptics. Whereas
in Zagreb the utilization of psycholeptics was twofold
their lowest consumption in Denmark, and by 23.6%
lower or 1.3-fold their highest consumption in Finland,
the utilization of psychoanaleptics was 2.3 times lower
than the lowest consumption in Finland but threefold
lower than the highest consumption in Sweden.
(Table 1 Utilization of psycholeptics (N05) and psycho-
analeptics (N06) in Zagreb and Scandinavian countries
during the years 2001–2003 expressed in the number of
DDD/TID – here)
The utilization distribution of psycholeptics from N05
group in Zagreb and Scandinavian countries is presented
in Fig. 1. There were no substantial differences between
Croatia (Zagreb) and Scandinavian countries, except
Sweeden, in the utilization of antipsychotics (N05A).
However, in contrast to Scandinavian countries where
the utilization of these drugs increased during the period
of observation with the highest rise recorded in Den-
mark, from 10.6 DDD/TID in 2001 to 11.9 DDD/TID in
2003, followed by Norway from 9.2 to 9.9 DDD/TID, Fin-
land from 12.52 to 13.01 DDD/TID, and lowest in Sweden
from 8.5 to 8.7 DDD/TID), in Zagreb the consumption of
these drugs decreased by 19.9%, i.e. from 15 DDD/TID in
2001 to 12 DDD/TID in 2003.
(Fig. 1 Distribution of utilization of antipsychotics
(N05A), anxiolytics (N05B), and hypnotics and sedatives
(N05C) from the group of psycholeptcs (N05) in Zagreb
and Scandinavian countries during the years 2001–2003,
expressed as percentage (%) – here)
The utilization distribution of anxiolytics showed sig-
nificant differences between Zagreb and Scandinavian
countries. During the period of observation, the utiliza-
tion of sedatives and hypnotics in Zagreb increased by
23%; with 14.75 DDD/TID in 2003 it was two times lower
than that in Denmark (32.7 DDD/TID), where no chan-
ges were recorded during the observation period; 2.5
times lower than that in Norway, where it increased from
2001 by 7.9% (36.9 DDD/TID in 2003); 3.3 times lower
than that in Sweden, where it increased by 1% in 2003
(49 DDD/TID); and 3.4 times lower than that in Finland,
where it increased from 2001 by 7.6% (50.8 DDD/TID in
2003).
In the N06 group, antidepressants (N06A) accounted
for more than 90% of utilization both in Zagreb and in
Scandinavian countries. Results on antidepressant utili-
zation are presented in Table 2. Total antidepressant
consumption was 2 to 3 times lower in Zagreb than in
Scandinavian countries.
(Table 2 Utilization of Non-selective monoamine reup-
take inhibitors (N06AA), Selective serotonin reuptake
inhibitors (N06AB), Monoamine oxidase A inhibitors
(N06AG), and Other antidepressants (N06AX), and over-
all utilization of antidepressants (N06A) in Zagreb and
Scandinavian countries during the years 2001–2003 ex-
pressed in the number of DDD/TID- here)
Outpatient drug utilization within and beyond DU90%
segment in 2003 was compared between Zagreb (Table 3)
and Finland (Table 4). Finland was chosen as the most
suitable country for this comparison9. Ten drugs fell un-
der DU90% segment in Zagreb and 24 in Finland. In
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Zagreb, the cost for DU90% segment accounted for 54.1%,
and the cost for the rest of 24 drugs for 45.9% of overall
financial expenses. In Finland, the cost for DU90% seg-
ment accounted for 81.8%, and the cost for the rest of 44
drugs for 18.2% of overall financial expenses.
(Table 3 Psycholeptics and psychoanaleptics within
Drug Utilization 90% (DU90%) segment expressed in the
number of DDD/TID, and cost per DDD in EUR within
and beyond DU90% segment in Zagreb in 2003 – here)
(Table 4 Psycholeptics and psychoanaleptics within
Drug Utilization 90% (DU90%) segment expressed in the
number of DDD/TID, and cost per DDD in EUR within
and beyond DU90% segment in Finland in 2003 – here)
Discussion
The results obtained in the study point to differences
in the psychopharmaceutical utilization pattern in pri-
mary health care between Zagreb and Scandinavian coun-
tries. The differences are partly consequential to differ-
ent socioeconomic and health policy factors in the two
settings. During the period of observation, the utilization
of psycholeptics decreased in Zagreb by 6.7%, remained
unchanged in Sweden and Denmark, and increased by
6.6% in Finland and by 6.8% in Norway. The utilization
of psychoanaleptics increased in all settings, showing
greatest rise in Zagreb (26.9%), followed by Denmark
(21.5%), Norway (17%), Finland (16.3%) and Sweden
(12%).
In the group of psycholeptics (N05), the utilization of
antipsychotics (N05A) was on a decline in Zagreb but on
a rise in Scandinavian countries (Fig.1). Typical antipsy-
chotics contributed to their decline in Zagreb. Various re-
cent recommendations and guidelines suggest that atypi-
cal antipsychotics should be preferred to typical antipsy-
chotics because of the lower rate of side effects, thus pre-
scribing of the former being on an increase in the majority
of European countries12. In Zagreb, the ratio of atypical
to typical antipsychotics was 1:2 in 2001 and 1:1.3 in
2003, still being less favorable in comparison with Scan-
dinavian countries. In Finland, the ratio was 1:1.6 in
2001 and 1:1.1 in 2003. In Norway, the ratio was 1:1.2 in
2001 and 1.2:1 in 2003. In Denmark, the ratio was in fa-
vor of atypical antipsychotics in 2001 (1.2:1) to show fur-
ther improvement in 2003 (1.78:1).
In Zagreb, anxiolytics (N05B) accounted for 90% and
80% of overall psycholeptic utilization in 2001 and 2003,
respectively, whereas in Scandinavian countries they ac-
counted for 22% (Sweden) through 34% (Finland) during
the period of observation. The distribution of sedative
and hypnotic (N05C) utilization showed an inverse pattern.
In Zagreb, benzodiazepines showed highest share in
the overall psycholeptic (N05) utilization. Ten benzodia-
zepines have been registered in Croatia, nine of them
psycholeptics and one antiepileptic (clonazepam). In 2003,
the share of benzodiazepines in the overall utilization of
psycholeptics in Zagreb amounted to 86.8%, although the
consumption of benzodiazepines showed a 6.25% decline
during the period of observation (from 112 DDD/TID in
2001 to 105 DDD/TID in 2003). Anxiolytics accounted for
92.8%, and hypnotics for 7.2% of this share. In Scandina-
vian countries, the share of benzodiazepines in the over-
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TABLE 1
UTILIZATION OF PSYCHOLEPTICS (N05) AND PSYCHOANALEPTICS (N06) IN ZAGREB AND SCANDINAVIAN





Zagreb Finland Sweden Norway Denmark
2001 129.8 86.4 74.0 62.6 65.6
N05 Psycholeptics 2002 129.3 89.5 74.2 65.5 65.9
2003 121.1 92.5 74.0 67.2 66.1
2001 15.2 40.0 57.3 46.3 42.4
N06 Psychoanaleptics 2002 18.8 43.7 63.3 50.5 47.8
2003 20.8 47.8 65.1 55.8 54.0
2001 144.9 126.4 131.3 108.9 108.0
Total 2002 148.1 133.2 137.5 116.0 113.7



















Fig. 1. Distribution of utilization of antipsychotics (N05A), an-
xiolytics (N05B), and hypnotics and sedatives (N05C) from the
group of psycholeptcs (N05) in Croatia (Zagreb) and Scandina-
vian countries during the years 2001–2003, expressed as
percentage (%).
all utilization of psycholeptics was 57.3% in Finland,
51.4% in Denmark, 43.2% in Norway, and 33.8% in Swe-
den. In Zagreb, the consumption of benzodiazepines in
2003 was twofold that in Finland (53 DDD/TID), three-
fold that in Denmark (34 DDD/TID), 3.6-fold that in Nor-
way (29 DDD/TID), and 4.7-fold that in Sweden (22
DDD/TID). In Scandinavian countries, benzodiazepine
related drugs (N05CF) accounted for a considerably higher
share in overall psycholeptic utilization, ranging from
28.6% in Denmark through 34% in Finland, whereas in
Zagreb they accounted for only 6.7% in 2003, yet showing
a fourfold increase from 2001 (from 2.3 to 8.11 DDD/
TID). Zolpidem is the only drug from this group regis-
tered in Croatia. As new generation hypnotics, benzo-
diazepine related drugs, are currently recommended to
use in therapy for insomnia, the consumption of these
drugs is also expected to rise in Croatia characterized by
excessive and uneconomical utilization of benzodiazepi-
nes, which has no true ground in therapeutic guide-
lines13–16. Such a high consumption of these drugs ex-
ceeds their consumption in any other European country
and can only be compared with that in neighboring coun-
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TABLE 3
PSYCHOLEPTICS AND PSYCHOANALEPTICS WITHIN DRUG UTILIZATION 90% (DU90%) SEGMENT EXPRESSED IN DDD/TID, AND
COST PER DDD IN EUR WITHIN AND BEYOND DU90% SEGMENT IN ZAGREB IN 2003
No. Drug name DDD Share (%) DDD/TID Cost/DDD
1 Diazepam 1,642,456 25.7 36.5 0.1
2 Oxazepam 1,142,343 17.9 25.4 0.2
3 Alprazolam 772,065 12.1 17.2 0.2
4 Lorazepam 503,700 7.9 11.2 0.1
5 Zolpidem 365,140 5.7 8.1 0.2
6 Bromazepam 359,208 5.6 8.0 0.2
7 Nitrazepam 264,180 4.1 5.9 0.1
8 Fluoxetine 260,708 4.1 5.8 0.6
9 Paroxetine 240,060 3.8 5.3 0.6
10 Sertraline 187,824 2.9 4.2 0.6
DU90% 1–10 5,737,684 89.9 127.6 0.2
Others 11–35 643,798.8 10.1 14.3 1.5
Total 1–35 6,381,482.8 100.0 141.9 0.3
TABLE 2
UTILIZATION OF NON-SELECTIVE MONOAMINE REUPTAKE INHIBITORS (N06AA), SELECTIVE SEROTONIN REUPTAKE INHIBITORS
(N06AB), MONOAMINE OXIDASE A INHIBITORS (N06AG), AND OTHER ANTIDEPRESSANTS (N06AX), AND OVERALL UTILIZATION OF





Zagreb Finland Sweden Norway Denmark
2001 5.2 4.0 4.0 4.2 4.6
N06AA Non-selective monoamine reuptake inhibitors 2002 4.6 3.9 4.0 4.1 4.4
2003 3.5 4.0 3.9 3.9 4.3
2001 9.1 24.8 42.2 32.0 28.8
N06AB Selective serotonin reuptake inhibitors 2002 13.4 26.9 46.4 33.5 32.3
2003 16.5 29.5 46.9 36.3 36.8
2001 0.0 1.1 0.3 0.5 0.1
N06AG Monoamine oxidase A inhibitors 2002 0.0 0.9 0.3 0.4 0.1
2003 0.1 0.8 0.3 0.4 0.1
2001 0.1 6.3 9.2 7.5 7.8
N06AX Other antidepressants 2002 0.1 7.5 10.6 9.6 9.5
2003 0.1 8.3 11.5 11.1 10.9
2001 15.2 40.0 57.3 46.3 42.4
Total 2002 18.8 43.7 63.3 50.5 47.8
2003 20.8 47.8 65.1 55.8 54.0
tries, which also lack clear guidelines and strict control
mechanisms of drug prescribing17,18.
During the period of observation, the utilization of
antidepressants (N06A) increased in all study settings,
however, the highest rise was recorded in Zagreb (26.9%),
followed by Denmark (21.5%), Norway (17.7%), Finland
(16.3%), and lowest rise in Sweden (12%), yet the latter
reporting highest antidepressant consumption, i.e. three-
fold that in Zagreb. In the group of antidepressants, Se-
lective serotonin reuptake inhibitors (SSRI) accounted
for the highest share of utilization and showed a rising
pattern in all study settings. In Zagreb, the use of SSRI
in 2003 increased almost twofold from 2001, accounting
for the highest share in overall antidepressant utilization
(80.3%). In Sweden, the respective share was 72%, with
lowest rise in consumption (10%). In Denmark, the share
of SSRI in overall utilization of antidepressants was
68.1%, with a rise of 21.7%. In Norway, the share of SSRI
in overall utilization of antidepressants was 65.1%, with
a rise of 11.9%. Finland reported the lowest share of
SSRI in overall antidepressant consumption (61.7%),
with a 15.9% rise from 2001 to 2003. In Zagreb, Non-
selective monoamine reuptake inhibitors (N06AA) were
the second most commonly prescribed drugs from the
group of antidepressants. These drugs showed a compa-
rable utilization in Zagreb and Scandinavian countries,
however, with a significantly greater tendency to decline
in Zagreb (32.7%) than in Scandinavian countries with a
decline by 7.1% in Norway, 6.5% in Denmark, and no
such changes in their utililzation during the period of ob-
servation reported from Finland and Sweden. Although
showing a considerable decline in utilization, this group
accounted for 16.8% of overall utilization of antidepres-
sants in Zagreb, whereas in Scandinavian countries this
share ranged from 6.0% in Sweden through 8.4% in Fin-
land. In Scandinavian countries Other antidepressants
(N06AX) ranked second in the group of antidepressants,
whereas in Zagreb the consumption of these drugs was
very low and rather uniform throughout the three study
years (0.1 DDD/TID). In Scandinavian countries, the uti-
lization of these drugs showed an increase of 32.4% in
Norway, 28.4% in Denmark, 24.1% in Finland, and 20%
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TABLE 4
PSYCHOLEPTICS AND PSYCHOANALEPTICS WITHIN DRUG UTILIZATION 90% (DU90%) SEGMENT EXPRESSED IN DDD/TID,
AND COST PER DDD IN EUR WITHIN AND BEYOND DU90% SEGMENT IN FINLAND IN 2003
No. Drug name DDD Share (%) DDD/TID Cost/DDD
1 Zopiclone 48,893,502 18.4 25.9 0.1
2 Temazepam 32,179,714 12.1 17.0 0.1
3 Citalopram 27,774,383 10.5 14.7 0.6
4 Diazepam 16,241,113 6.1 8.6 0.1
5 Alprazolam 13,915,552 5.2 7.4 0.2
6 Oxazepam 13,348,342 5.0 7.1 0.2
7 Fluoxetine 11,306,386 4.3 6.0 0.4
8 Zolpidem 9,585,849 3.6 5.1 0.2
9 Mirtazapine 8,148,917 3.1 4.3 1.2
10 Sertraline 7,373,730 2.8 3.9 0.9
11 Paroxetine 6,919,962 2.6 3.7 0.9
12 Lorazepam 5,407,402 2.0 2.9 0.2
13 Venlafaxine 5,218,332 2.0 2.8 1.3
14 Olanzapin 4,915,820 1.9 2.6 4.8
15 Amitriptyline 4,254,075 1.6 2.3 0.2
16 Donepezil 3,327,632 1.3 1.8 3.3
17 Nitrazepam 3,062,934 1.2 1.6 0.1
18 Risperidon 2,873,864 1.1 1.5 4.6
19 Amitriptyline+psyc 2,722,608 1.0 1.4 0.3
20 Clozapine 2,684,794 1.0 1.4 2.2
21 Chlordiazepoxide 2,004,142 0.8 1.1 0.1
22 Hydroxyzine 1,947,421 0.7 1.0 0.5
23 Doxepin 1,928,514 0.7 1.0 0.3
24 Perphenazine 1,890,700 0.7 1.0 0.5
DU90% 1–24 237,925,688 89.7 125.8 0.5
Others 25–69 27,396,243 10.3 14.5 1.0
Total 1–69 265,321,931 100.0 140.3 0.6
in Sweden, where the highest consumption was recorded.
While in Zagreb the drugs from this group including se-
rotonin and norepinephrine reuptake inhibitors (SNRI)
accounted for only 0.5% of overall antidepressant utiliza-
tion, in Scandinavian countries their share ranged from
17.4% in Finland through 20.2% in Denmark. Although
recent studies suggest that drugs from this group may be
a cost-effective option compared with SSRI and tricyclic
antidepressants (TCA) when used as a first-line drug for
depression in primary care19, only tianeptin and rebo-
xetin were registered in Croatia until 2003, whereas
venlafaxin was only registered in 2004.
The ratio of anxiolytics to antidepressants has also
been used as an indicator of psychopharmaceutical pre-
scribing quality in a particular setting, whereby antide-
pressants as etiological therapy should prevail20,21. This
ratio revealed significant differences between Zagreb and
Scandinavian countries. In Zagreb, it was 7.19 in 2001
and 4.66 in 2003. While this index points to a 35.2% de-
cline over three years of observation, these data question
the appropriateness of current pharmacological treat-
ments, particularly for major depression, in which under-
treatment is coupled with the high use of nonspecific
medications such as anxiolytics, primarily benzodiaze-
pines, in Zagreb23. In Scandinavian countries, this ratio
was generally constant during the study period, i.e. 0.7 in
Finland, 0.4 in Denmark and Norway, and 0.3 in Sweden.
In Croatia, there is an obvious tendency to follow the
western trends in drug prescribing, as demonstrated by
the increased consumption of antidepressants and re-
duced use of anxiolytics, however, greater efforts need to
be invested.
The price of a drug is an important factor determin-
ing its inclusion in the CIHI List of Drugs, as illustrated
by comparison of drug consumption within DU90% seg-
ment between Zagreb and Finland. In Finland, twice as
many drugs from these groups have been registered, and
2.5 as many drugs fall in DU90% segment as in Zagreb.
In Zagreb, six of the ten drugs in DU90% segment are
benzodiazepines, inexpensive drugs, one is a benzodiaz-
epine related drug, zolpidem, and three are antidepres-
sants from the SSRI group. In Zagreb, the cost/DDD ra-
tio within DU90% segment is 7.5 times lower than the
same ratio for drugs beyond DU90% segment. In Fin-
land, however, the drugs falling within DU90% segment
yield a two times lower cost/DDD ratio than those be-
yond DU90% segment, whereby drugs like mirtazapine,
a SNRI, which has only recently been registered in
Croatia, then venlafaxine, the antipsychotics olanzapine,
risperidon and clozapine with usage restrictions charged
to the national health insurance in Croatia, and done-
pezil that is not on the CIHI List of Drugs, fall within
DU90% segment. The fact that GNP per capita is 9,441.38
EUR in Croatia and 33,674.2 EUR in Finland certainly
reflects in the policy of the national health insurance
companies. In Croatia, the inclusion of drugs in the CIHI
List of Drugs depends on the limited national budget.
Yet, comprehensive pharmacoeconomic analyses justify-
ing the inclusion of particular drugs in the CIHI List of
Drugs have not been performed, the primary criteria be-
ing the price of the drug and its efficacy. In addition, clear
prescription guidelines for these drugs are still lacking,
while monitoring of drug consumption has only recently
been regulated at the national level. In such a situation,
a number of factors play quite important role, e.g., ag-
gressive marketing of pharmaceutical industries, which
has not been properly regulated either; escalating de-
mands from patients for medication prescriptions; and
developments reported in medical literature24.
Conclusions
In spite of the limitations of this study related to our
sampling used to determine drug utilization, limitations
of the ATC/DDD methodology, and use of DU90% seg-
ment providing only a rough insight in the prescribing
quality, our rough data on the utilization of psychotropic
drugs in Zagreb indicated an excessive utilization of
benzodiazepines in Croatia as a whole, although it is
likely to be lower at the national level. The consumption
of these drugs is too high and uneconomic, obviously call-
ing for appropriate education of both physicians and pa-
tients to reduce it to an acceptable level.
The three-year utilization patterns observed for the
groups of psycholeptics and of psychoanaleptics, along
with changes in the consumption of drugs, primarily an-
tidepressants, show that Croatia has been ever more
closely following Scandinavian countries in the field al-
though there have been a notable difference between
Zagreb and Scandinavian countries yet. The utilization
of antipsychotics were decreased in Zagreb, in contrast to
Scandinavian countries where the utilization of these
drugs increased. In Zagreb, the ratio of atypical to typical
antipsyhotics was less favorable in comparison to Scandi-
navian countries. The ratio of anxiolytic to antidepre-
sssants revealed significant differences between Zagreb
and Scandinavian countries.
The price of a drug is an important factor determin-
ing its inclusion in the CIHI List of Drugs. The general
insight in the quality of psychopharmaceutical prescrib-
ing points to a lower level in Zagreb as compared with
Finland. Therefore, first of all, clear guidelines for pre-
scribing psychopharmaceuticals should be designed; phar-
macoeconomic analysis should be introduced on includ-
ing drugs on the CIHI List of Drugs; and problems
should be more precisely defined and priorities identified
through monitoring of drug utilization at the national
level.
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IZVANBOLNI^KA POTRO[NJA PSIHOFARMAKA: USPOREDBA IZME\U HRVATSKE
I SKANDINAVSKIH ZEMALJA OD 2001.–2003.
S A @ E T A K
Cilj rada je bio procjeniti izvanbolni~ku potro{nju psihofarmaka u Hrvatskoj, u korelaciji sa potro{njom u skan-
dinavskim zemljama. Na temelju podataka Gradske ljekarne Zagreb o broju pakovanja, izra~unat je broj definiranih
dnevnih doza (DDD) i broj definiranih dnevnih doza na 1000 stanovnika na dan (DDD/1000/dan), koriste}i Anatom-
sko-Terapijsko-Kemijsku klasifikaciju lijekova (ATK). Podaci o potro{nji lijekova u skandinavskim zemljama dobiveni
su od Skandinavskog medicinsko-statisti~kog vije}a. U Zagrebu, ukupna potro{nja psihofarmaka se kretala od 144.9
DDD/1000/dan u 2001. do 148.9 DDD/1000/dan u 2002. i 141,9 DDD/1000/dan u 2003. godini. Odnos anksiolitici/anti-
depresivi se u Hrvatskoj smanjio za 35,19% (7,19 u 2001. i 4,66 u 2003. godini), dok je ovaj odnos u skandinavskim
zemljama ostao gotovo nepromijenjen (0,7 u Finskoj, 0,4 u Danskoj i Norve{koj, 0,3 u [vedskoj). Rezultati ovog istra-
`ivanja pokazuju da postoje zna~ajne razlike u propisivanju psihofarmaka izme|u Hrvatske i skandinavskih zemalja,
iako Hrvatska u promatrane tri godine po~inje slijediti skandinavske zemlje.
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